Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics, Inc. develops RNA and immuno-oncology therapeutics for high-risk and advanced cancers. News about RNAZ centers on its lead candidate TTX-MC138, an antagomiR targeting microRNA-10b, along with preclinical publications, IND-related clinical updates, research collaborations and sponsored research tied to RNA-targeted oncology.
Company updates also cover additions to its early-stage oncology pipeline, including adenovirus-based oncolytic immunotherapy candidates UIO-524, UIO-525 and UIO-526, as well as governance changes involving its board and scientific advisory structure. Capital-structure announcements, material agreements and operating or financial results are recurring disclosure themes for this clinical-stage biotechnology issuer.
TransCode Therapeutics (NASDAQ: RNAZ) reported its Q1 2022 financial results, highlighting a cash position of $16.9 million. The company plans to submit an exploratory IND application for its lead candidate, TTX-MC138, in a Phase 0 study targeting advanced solid tumors. Financially, expenses rose significantly, with R&D costing $1.9 million and a total operating loss of $3.5 million. TransCode achieved a milestone in its SBIR grant and aims for further funding to support ongoing projects and team expansions, while also filing for new patents in RNA oncology.
TransCode Therapeutics (NASDAQ: RNAZ) announced that Dr. Zdravka Medarova will moderate the 7th Annual RNA Medicine Symposium on April 28, 2022. The event, co-sponsored by Harvard Medical School and Beth Israel Deaconess Medical Center, will feature esteemed speakers from various prestigious institutions. Dr. Medarova will also present at the 3rd Annual RNAi-Based Therapeutics Summit, discussing novel siRNA-based therapies for cancer, including their applications and the potential of RNAi in tumor targeting. TransCode aims to advance RNA oncology therapeutics to improve patient outcomes.
TransCode Therapeutics (NASDAQ: RNAZ) announced its financial results for 2021 and highlighted significant business advancements.
Key achievements included an over-subscribed IPO raising $28.8 million and the award of a $2.3 million SBIR grant for the clinical evaluation of its lead candidate, TTX-MC138.
The company plans to submit an eIND application to the FDA for TTX-MC138 and initiate a Phase 0 study in Stage IV cancer patients in 2022. As of December 31, 2021, TransCode had $20.8 million in cash, sufficient to fund operations into early 2023.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced that an interview with CEO Michael Dudley will be broadcasted on The RedChip Money Report® on Bloomberg TV on March 26 at 7 p.m. ET. The report aims to provide insights into small-cap investing and features financial commentary and public company interviews. TransCode focuses on RNA therapeutics to combat cancer, with lead candidate TTX-MC138 targeting metastatic cancer. This condition accounts for about 90% of cancer deaths globally, totaling over nine million annually.
TransCode Therapeutics (NASDAQ: RNAZ) published an article in Cancers discussing the advancements in short RNA-based therapeutics for cancer and other diseases. Co-authored by Dr. Anna Moore, the article explores the design, modification, and delivery of these RNA drugs. Key insights include the potential of RNA therapeutics to revolutionize treatment methods, particularly in personalized cancer therapy. CEO Michael Dudley announced plans for a first-in-human trial of the lead candidate, TTX-MC138, aimed at targeting metastatic disease, which accounts for 90% of cancer deaths.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has filed an International PCT Application (PCT/US21/65580) for its novel cancer therapy entitled TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY. This application expands the company's RNA therapeutic platform to activate the RIG-I signaling pathway, potentially leading to tumor cell death and enhancing the immune response against cancer. The patent aims to allow for personalized cancer treatments using TransCode's TTX delivery platform, which targets various RNA therapies for different tumor types.
TransCode Therapeutics (Nasdaq: RNAZ) has announced its participation at the 2022 BIO CEO & Investor Conference, scheduled for February 14-17, 2022. CEO Michael Dudley will present the company's RNA-based innovations aimed at combating cancer, particularly highlighting the lead candidate, TTX-MC138, intended for metastatic disease treatment. An exploratory Investigational New Drug (eIND) application with the FDA is expected to be filed in the second half of 2022 to initiate a first-in-human trial for Stage IV breast cancer patients.
TransCode Therapeutics (RNAZ) is set to present at the 2022 BIO CEO & Investor Conference from February 14-17, 2022. CEO Michael Dudley will discuss the company's RNA-based innovations aimed at advancing cancer treatment, particularly their lead candidate for metastatic disease. An exploratory Investigational New Drug application (eIND) is expected to be filed with the FDA in the second half of 2022, paving the way for a First-in-Human clinical trial targeting Stage IV breast cancer. The presentation will be streamed live and available for later viewing.
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) will attend and present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Michael Dudley will discuss the company's RNA-based cancer treatments, focusing on its lead candidate, TTX-MC138, which aims to enter its First in Human clinical trial in 2022. The presentation is scheduled for January 10, 2022, at 7:00 AM ET and will be webcast, with an archived recording available for 90 days on TransCode's website.
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) announced its participation at the MedInvest Oncology Investor Conference. CEO Michael Dudley will present the company's RNA-based advancements in cancer treatment, including their lead candidate, TTX-MC138, targeting metastatic cancer with a first human trial expected in mid-2022. The presentation is scheduled for December 7th at 2:50 PM EST and will be available via webcast. TransCode aims to improve outcomes for various cancers, responsible for approximately 90% of cancer deaths globally.